Psoriasis Disease
Vilacto Bio™ treats a wide range of inflammatory abnormalities, inflammation related disorders (both acute and chronic) and is well within the capacity of our patented properties (Lactoactive®).
We have already overcome notorious healing challenges for some of those concerns, like such wounds, psoriasis, vitiligo, and autoimmune related skin conditions.
Our products are currently available on the market as Vilact®. Our aim is to develop new drugs and treatment based on our current treatments to help more people suffering from debilitating skin conditions.
Synopsis on psoriasis as a chronic disease with a high comorbidity
Psoriasis’s Facts in the USA:
7.5 million Americans – approximately 2.2% of the population – have psoriasis.
The annual cost for treating psoriasis in the US is estimated as high as $32.5 billion - $12.2 billion in direct costs.
Expenses linked to co-morbidities are estimated at an additional $23,000 per patient per year.
Approximately 80% of those affected with psoriasis have mild to moderate disease, while 20% have moderate to severe psoriasis affecting more than 5% of the body surface area.
Global Psoriasis’s Facts
125 million people worldwide – 2% to 3% of the total population – have psoriasis.
About one out of three people with psoriasis report having a relative with psoriasis as well.
Total direct and indirect health care costs of psoriasis for patients have calculated at $11.25 billion annually, with work loss accounting for 40% of the cost burden.
Annual Growth Rate (AGR) of 1.53% estimated till 2024.
World map showing the DALYs for psoriasis per 100 000, rates for all ages and both sexes.
One DALY equals one lost year of an otherwise healthy life.
References:
WHO Global report on psoriasis 2016